# US 7,612,183 B2 · Humanised anti-mag antibody or functional fragment thereof > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 7,612,183 B2 - Document ID: US7612183B2 - Status: Granted - Kind: B2 - Application number: 10/523,295 - Filed: 2003-08-05 - Published: 2006-07-27 - Granted: 2009-11-03 - Earliest claimed: 2002-08-06 - Assignees: Glaxo Group Limited - Inventors: Jonathan Henry Ellis; Volker Germaschewski - Web page: https://patentgrep.com/patent/US7612183B2 ## CPC - C07K 16/28: against receptors, cell surface antigens or cell surface determinants - A61P 25/00: Drugs for disorders of the nervous system - A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia - A61P 25/16: Anti-Parkinson drugs - A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia - A61P 37/00: Drugs for immunological or allergic disorders - A61K 2039/505: {comprising antibodies} - A61K 2039/54: {characterised by the route of administration} - C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered - C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) ## Abstract The present invention relates to altered antibodies to myelin associated glycoprotein (MAG), pharmaceutical formulations containing them and to the use of such antibodies in the treatment and/or prophylaxis of neurological diseases/disorders. ## Claims ### Claim 1 A humanised anti-MAG antibody which binds to and neutralizes MAG comprising, a heavy chain variable domain selected from the group consisting of: SEQ ID No. 13, SEQ ID No. 14, and SEQ ID No. 15, and a light chain variable domain selected from the group consisting of: SEQ ID No. 16, SEQ ID No. 17, SEQ ID No. 18, and SEQ ID No. 19. ### Claim 2 (depends on 1) A pharmaceutical composition comprising a humanised anti-MAG antibody which binds to and neutralizes MAG according to claim 1, further comprising a pharmaceutically acceptable diluent or carrier. ### Claim 3 (depends on 1) The humanised anti-MAG antibody which binds to and neutralizes MAG according to claim 1, further comprising a constant part or fragment thereof of a human light chain and a constant part or fragment thereof of a human heavy chain. ### Claim 4 A humanised anti-MAG antibody which binds to and neutralizes MAG comprising: a heavy chain variable region of SEQ ID No. 13 and a light chain variable region of SEQ ID No. 16. ### Claim 5 A humanised anti-MAG antibody which binds to and neutralizes MAG comprising: a heavy chain variable region of SEQ ID No. 13 and a light chain variable region of SEQ ID No. 17. ### Claim 6 A humanised anti-MAG antibody which binds to and neutralizes MAG comprising: a heavy chain variable region of SEQ ID No. 13 and a light chain variable region of SEQ ID No. 18. ### Claim 7 A humanised anti-MAG antibody which binds to and neutralizes MAG comprising: a heavy chain variable region of SEQ ID No. 13 and a light chain variable region of SEQ ID No. 19. ### Claim 8 A humanised anti-MAG antibody which binds to and neutralizes MAG comprising: a heavy chain variable region of SEQ ID No. 14 and a light chain variable region of SEQ ID No. 16. ### Claim 9 A humanised anti-MAG antibody which binds to and neutralizes MAG comprising: a heavy chain variable region of SEQ ID No. 14 and a light chain variable region of SEQ ID No. 17. ### Claim 10 A humanised anti-MAG antibody which binds to and neutralizes MAG comprising: a heavy chain variable region of SEQ ID No. 14 and a light chain variable region of SEQ ID No. 18. ### Claim 11 A humanised anti-MAG antibody which binds to and neutralizes MAG comprising: a heavy chain variable region of SEQ ID No. 14 and light chain variable region of SEQ ID No. 19. ### Claim 12 A humanised anti-MAG antibody which binds to and neutralizes MAG comprising: a heavy chain variable region of SEQ ID No. 15 and a light chain variable region of SEQ ID No. 16. ### Claim 13 A humanised anti-MAG antibody which binds to and neutralizes MAG comprising: a heavy chain variable region of SEQ ID No. 15 and a light chain variable region of SEQ ID No. 17. ### Claim 14 A humanised anti-MAG antibody which binds to and neutralizes MAG comprising: a heavy chain variable region of SEQ ID No. 15 and a light chain variable region of SEQ ID No. 18. ### Claim 15 A humanised anti-MAG antibody which binds to and neutralizes MAG comprising: a heavy chain variable region of SEQ ID No. 15 and a light chain variable region of SEQ ID No. 19.